Generic Derma-Smoothe/FS Availability
Last updated on May 7, 2025.
Derma-Smoothe/FS is a brand name of fluocinolone topical, approved by the FDA in the following formulation(s):
DERMA-SMOOTHE/FS (fluocinolone acetonide - oil;topical)
-
Manufacturer: HILL DERMAC
Approval date: February 3, 1988
Strength(s): 0.01% [RLD] [AT] -
Manufacturer: HILL DERMAC
Approval date: November 9, 2005
Strength(s): 0.01% [RLD] [AT]
Is there a generic version of Derma-Smoothe/FS available?
Yes. The following products are equivalent to Derma-Smoothe/FS:
FLUCINOLONE ACETONIDE (fluocinolone acetonide oil;topical)
-
Manufacturer: GLENMARK PHARMS LTD
Approval date: October 25, 2018
Strength(s): 0.01% [AT]
fluocinolone acetonide oil;topical
-
Manufacturer: NOVEL LABS INC
Approval date: July 31, 2023
Strength(s): 0.01% [AT] -
Manufacturer: NOVEL LABS INC
Approval date: August 7, 2023
Strength(s): 0.01% [AT] -
Manufacturer: PADAGIS ISRAEL
Approval date: August 9, 2013
Strength(s): 0.01% [AT], 0.01% [AT] -
Manufacturer: QUAGEN
Approval date: April 2, 2021
Strength(s): 0.01% [AT], 0.01% [AT] -
Manufacturer: RISING
Approval date: April 25, 2016
Strength(s): 0.01% [AT], 0.01% [AT] -
Manufacturer: TARO
Approval date: May 19, 2016
Strength(s): 0.01% [AT], 0.01% [AT]
FLUOCINONIDE ACETONIDE (fluocinolone acetonide oil;topical)
-
Manufacturer: GLENMARK PHARMS LTD
Approval date: October 26, 2018
Strength(s): 0.01% [AT]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Derma-Smoothe/FS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Derma-Smoothe / FS (fluocinolone topical)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: topical steroids
- Breastfeeding
Patient resources
Other brands
Synalar, Derma-Smoothe/FS (Body Oil), Capex
Professional resources
Other brands
Synalar, Capex, Synalar Ointment
Other formulations
Related treatment guides
Related/similar drugs
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Clobetasol topical
Clobetasol is available as a cream, gel, ointment, lotion, solution, foam or spray and is used to ...
Betamethasone topical
Betamethasone topical is available as a cream, gel, ointment, lotion, foam or spray and treats ...
Ketoconazole topical
Ketoconazole topical is used for androgenetic alopecia, cutaneous candidiasis, dandruff, seborrheic ...
Hydrocortisone topical
Hydrocortisone cream is used to treat eczema, dermatitis, psoriasis, hemorrhoids, insect bites or ...
Triamcinolone
Triamcinolone is used to treat allergies, skin conditions, ulcerative colitis, and arthritis. Learn ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AT | Topical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.